SH-11037

Overview

SH-11037 is a potent inhibitor of soluble epoxide hydrolase ( sEH ) and docks to the substrate binding cleft in the sEH hydrolase domain. SH-11037 dose-dependently suppresses angiogenesis in the choroidal sprouting assay ex vivo and inhibited ocular developmental angiogenesis in zebrafish larvae. SH-11037 reduces choroidal neovascularisation lesion volume in the laser-induced CNV mouse model. SH-11037 synergises with anti- VEGF treatments in vitro and in vivo. SH-11037 induces G2/M phase blockade and retains retinal endothelial cell viability at active concentrations without overt toxicity. SH-11037 can be used for the research of retinal neovascularization and ocular neovascularization.

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Visual System Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > Epoxide Hydrolase

Product Information

• Catalog No.: HY-182372
• CAS No.: 1638153-78-2
• Molecular Formula: C34H39NO10
• Molecular Weight: 621.67
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source